###begin article-title 0
###xml 79 85 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
The Association Between the Peroxisome Proliferator-Activated Receptor-gamma2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis
###end article-title 0
###begin p 1
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Editor's note</italic>
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Editor's note</italic></bold>
###xml 13 99 13 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">: This article also appears on the Web site of the Human Genome Epidemiology Network (<ext-link ext-link-type="uri" xlink:href="http://www.hugenet.org.uk/index.html">http://www.hugenet.org.uk/index.html</ext-link>).</italic>
###xml 64 69 <span type="species:ncbi:9606">Human</span>
Editor's note: This article also appears on the Web site of the Human Genome Epidemiology Network ().
###end p 1
###begin p 2
###xml 59 64 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 518 523 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 713 718 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1063 1064 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 1064 1065 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1188 1193 1184 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 199 204 <span type="species:ncbi:9606">Human</span>
The peroxisome proliferator-activated receptor-gamma gene (PPARG) has been implicated in the etiology of type 2 diabetes mellitus and has been investigated in numerous epidemiologic studies. In this Human Genome Epidemiology review, the authors assessed this relation in an updated meta-analysis of 60 association studies. Electronic literature searches were conducted on September 14, 2009. Population-based cohort, case-control, cross-sectional, or genome-wide association studies reporting associations between the PPARG Pro12Ala gene variant (rs1801282) and type 2 diabetes were included. An updated literature-based meta-analysis involving 32,849 type 2 diabetes cases and 47,456 controls in relation to the PPARG Pro12Ala variant was conducted. The combined overall odds ratio, calculated by per-allele genetic model random-effects meta-analysis for type 2 diabetes and the Pro12Ala polymorphism, was 0.86 (95% confidence interval: 0.81, 0.90). The analysis indicated a moderate level of heterogeneity attributable to genuine variation in gene effect size (I2 = 37%). This may reflect the variation observed between ethnic populations and/or differences in body mass index. Work on PPARG Pro12Ala should now focus on the observed heterogeneity in the magnitude of the association between populations. Further investigations into gene-gene and gene-environment interactions may prove enlightening.
###end p 2
###begin title 3
BACKGROUND
###end title 3
###begin title 4
Gene/gene variants
###end title 4
###begin p 5
###xml 170 171 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 402 403 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 404 405 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 501 507 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
The peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-delta, and PPAR-gamma) are transcription factors belonging to the nuclear hormone receptor superfamily (1). These receptors combine with the retinoid X receptors to form heterodimers that regulate various genes involved in lipid and glucose metabolism, fatty acid transport, adipocyte differentiation, carcinogenesis, and inflammation (2-4). Here we consider the relation between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) gene and type 2 diabetes.
###end p 5
###begin p 6
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG1</italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 869 870 869 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 995 1002 995 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 790 795 <span type="species:ncbi:9606">Human</span>
The PPARG gene is located on chromosome 3p25 (OMIM number 601487) and encodes a nuclear transcription factor involved in the expression of hundreds of genes. The PPARG gene contains 9 exons, spans more than 100 kilobases, and, because of alternative mRNA splicing, results in the production of 2 protein isoforms, PPARG1 and PPARG2 (5). PPARG1 is encoded by 8 exons, using exons 1-6, A1, and A2, with PPARG2 being encoded using exons 1-6 and B. While PPARG1 is found ubiquitously in the body, PPARG2 is largely found in adipose tissue and the large intestine (5). Several variants in the PPARG gene have been identified, with the Pro12Ala variant having been the most extensively examined in epidemiologic studies. The PPARG gene locus and gene variants have previously been addressed in a Human Genome Epidemiology (HuGE) review on the genetics of leptin and obesity (6). The association between the Pro12Ala variant (rs1801282) and type 2 diabetes has been the focus of several meta-analyses (Table 1).
###end p 6
###begin p 7
###xml 107 113 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
Findings From Previously Conducted Meta-Analyses of the Peroxisome Proliferator-Activated Receptor-gamma2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes, 2000-2007
###end p 7
###begin p 8
Abbreviations: CI, confidence interval; NS, not stated; OR, odds ratio.
###end p 8
###begin p 9
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
The 95% CI was estimated using the P value (P = 0.0007) from the paper by Altshuler et al. (30).
###end p 9
###begin p 10
The risk allele was defined as Pro12.
###end p 10
###begin p 11
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
The OR and 95% CI were estimated from Figure 9 in the paper by Hara et al. (33).
###end p 11
###begin title 12
Gene variant frequency
###end title 12
###begin p 13
###xml 12 13 12 13 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 386 393 386 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Journal</italic>
###xml 217 223 <span type="species:ncbi:9606">people</span>
Yen et al. (7) first identified a missense mutation resulting in the alanine substitution for proline at codon 12 of the PPARG gene. The frequency of the 12Ala allele has been found to range from 2% to 18% in healthy people (6). We estimated Pro12Ala allele frequencies from the control groups of all studies identified for inclusion in the present review (see , which is posted on the Journal's Web site ()). Across all studies, the frequency of the 12Ala allele in control groups ranged from 1.7% to 21.6% (median, 9.5%). In the studies reporting controls as ethnically Caucasian, the 12Ala allele frequency ranged from 5.9% to 21.6% (median, 12.7%). In studies reporting controls as ethnically of East Asian descent (such as Chinese or Japanese), the 12Ala allele frequency ranged from 1.7% to 9.3% (median, 4.5%).
###end p 13
###begin title 14
Disease
###end title 14
###begin p 15
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 640 641 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 803 804 803 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 119 125 <span type="species:ncbi:9606">people</span>
###xml 1266 1273 <span type="species:ncbi:9606">persons</span>
By the year 2030, diabetes mellitus is expected to affect almost 5% of the world's population-an estimated 366 million people (8). The vast majority of these cases will be type 2 diabetes, with current diagnoses currently accounting for approximately 90%-95% of diabetes cases. Diabetes prevalence is currently about 3% in the general population, with increased prevalence in some ethnic minority groups (such as South Asians, Africans, Afro-Caribbeans, and Chinese), as well as in less affluent populations, including those that are less physically active, have central obesity, and have a high body mass index (BMI; weight (kg)/height (m)2). Some populations, such as Pima Indians, Australian Aboriginal communities, and Pacific and Indian Ocean Islanders, have a far higher prevalence, at up to 40% (9). The presence of diabetes mellitus is associated with a range of vascular complications (such as myocardial infarction, stroke, heart failure, renal failure, angina, and retinopathy) leading to a reduced life expectancy and a reduced quality of life (10). The large and increasing burden of type 2 diabetes and the potential for modifying risk through adequate treatments and lifestyle alterations make the identification of methods for the early detection of persons at greater risk an important public health challenge.
###end p 15
###begin p 16
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 443 449 443 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KCNJ11</italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 532 539 532 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAMTS9</italic>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKAL1</italic>
###xml 549 557 549 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A/B</italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CAMK1D</italic>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FTO</italic>
###xml 572 580 572 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HHEX/IDE</italic>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF1B</italic>
###xml 589 596 589 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2BP2</italic>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JAZF1</italic>
###xml 605 611 605 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTNR1B</italic>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOTCH2</italic>
###xml 621 628 621 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC30A8</italic>
###xml 630 635 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THADA</italic>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSPAN8</italic>
###xml 649 653 649 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WFS1</italic>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
Knowledge of genetic polymorphisms that allow accurate quantification of type 2 diabetes risk will allow the development of complex models with diagnostic and prognostic potential. Several extensive reviews have summarized findings on the genetic epidemiology of type 2 diabetes (11-13). However, substantial advances have been made in the past few years, with an increase in confirmed type 2 diabetes susceptibility loci from 3 genes (PPARG, KCNJ11, and TCF7L2) to almost 20 (with newly identified variants in the following genes: ADAMTS9, CDKAL1, CDKN2A/B, CAMK1D, FTO, HHEX/IDE, HNF1B, IGF2BP2, JAZF1, MTNR1B, NOTCH2, SLC30A8, THADA, TSPAN8, and WFS1) (14-17). This major step forward has been due mainly to advances in technology, with genome-wide association scans now allowing unprecedented progress to be made in the understanding of the genetic etiology of several complex diseases, including type 2 diabetes. It is increasingly evident that the genetic basis of type 2 diabetes involves multiple genes that each have a modest effect size on diabetes susceptibility and that interaction with other susceptibility loci and/or environmental factors may result in more substantial effects.
###end p 16
###begin title 17
Objectives
###end title 17
###begin p 18
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
###xml 294 301 294 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Journal</italic>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 738 743 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 471 476 <span type="species:ncbi:9606">Human</span>
The association between the PPARG2 Pro12Ala gene variant and type 2 diabetes has been investigated in numerous epidemiologic studies since it was first suggested in 1998 that carriers of the 12Ala variant showed a 75% reduction in risk of type 2 diabetes (see  (W1), which is listed in  on the Journal's Web site ()). Here we evaluate the evidence for an association between the PPARG2 Pro12Ala (rs1801282) gene variant and type 2 diabetes using methods developed by the Human Genome Epidemiology Network and the Cochrane Collaboration (18-20). We report results from an updated meta-analysis of 60 association studies, involving a total of 32,849 type 2 diabetes cases and 47,456 controls in relation to the Pro12Ala gene variant in the PPARG gene. The present report primarily focuses on population association studies (including case-control, cohort, and genome-wide association studies but excluding family-based studies) and contains an investigation of potential sources of heterogeneity.
###end p 18
###begin title 19
MATERIALS AND METHODS
###end title 19
###begin title 20
Selection criteria and identification of studies
###end title 20
###begin p 21
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
Eligible for inclusion were all population-based cohort, case-control, or cross-sectional studies reporting on associations between the PPARG2 Pro12Ala variant and type 2 diabetes. We performed electronic searches, not limited to the English language, of Medline (using PubMed), EMBASE, HuGE Navigator, Web of Science, and the Science Citation Index using the search method described in  (). The latest searches were undertaken on September 14, 2009. All relevant articles identified through the search were scanned on the basis of title, keywords, and abstract (where available) by one of us and were rejected in the initial screening if the article clearly did not meet the inclusion criteria. Where a title/abstract could not be rejected with certainty, we obtained the full text of the article for evaluation. We also reviewed the reference lists of retrieved articles to identify other relevant publications.
###end p 21
###begin p 22
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
In addition, we searched specifically for genome-wide association studies of type 2 diabetes using the catalog of published genome-wide association studies (21). The latest searches were undertaken on September 14, 2009. The full text and any supplementary materials were collected for each study identified. Data for the Pro12Ala single nucleotide polymorphism (SNP) (rs1801282) were extracted from each report, and study authors were contacted if insufficient data were reported.
###end p 22
###begin title 23
Data collection
###end title 23
###begin p 24
###xml 354 360 <span type="species:ncbi:9606">people</span>
###xml 485 496 <span type="species:ncbi:9606">participant</span>
The following data were extracted independently by at least 2 investigators, using a piloted data extraction form (with any discrepancies being resolved by discussion and, when necessary, adjudicated by a third reviewer): genotype frequencies by case/control status; mean ages of cases and controls; proportions of males and ethnic subgroups (defined as people of European continental ancestry, East Asian ancestry, or other); genotyping methods; and blinding of laboratory workers to participant case/control status. We calculated allele frequencies from control groups of studies that presented data on all 3 genotype groups, assuming Hardy-Weinberg equilibrium where appropriate. Where there were multiple publications from the same study group, we extracted data from each report and selected only the most complete and up-to-date data. When articles presented data for different ethnic groups or different case or control sources, results for the subgroups were considered as separate studies. Where data could not be extracted for inclusion in the meta-analysis, the investigators were contacted via letter and e-mail. Selected articles also included 4 Chinese-language publications, from which data were available from the English-language abstract (W2-W5).
###end p 24
###begin title 25
Data analysis
###end title 25
###begin p 26
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
The primary analyses for which results are presented were conducted using a per-allele inheritance model. This was the model favored by an initial analysis using the inheritance-model-free analysis of Minelli et al. (22) (data not shown). We estimated the per-allele odds ratio using logistic regression within each study. We used funnel plots and associated tests to assess assumptions involved in meta-analysis and to explore the relation between precision and magnitude of association (23). The meta-analyses used a standard approach, weighting by precision and incorporating random effects to allow for the variation in true associations across studies (24). We performed a cumulative meta-analysis to demonstrate how evidence concerning the genetic association has evolved over time.
###end p 26
###begin p 27
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
Consistency of the gene effect sizes across studies was assessed using a test for heterogeneity and the I2 statistic, which describes the percentage of total variation in point estimates attributable to genuine variation rather than sampling error (25). We further explored this variation by prespecified subgrouping of studies according to sample size (<100, 100-499, or >/=500), ethnicity (Caucasian or East Asian), source of controls (general population or hospital), study design (retrospective or prospective), and blinding of genotyping to clinical outcome (yes, no, or unknown). We used random-effects meta-regression to explore the extent to which these subgroups could explain the between-study variance. Fixed-effect meta-analyses were conducted as sensitivity analyses. All ranges presented are 95% confidence intervals unless otherwise specified.
###end p 27
###begin p 28
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SYN2</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
Only summary meta-analysis results were available from Zeggini et al. (26). Their analysis used imputed and genotyped data for the SYN2/PPARG region, including either the rs17036101 SNP or the rs1801282 SNP, as these 2 SNPs represent the same association signal. Using the rs17036101 SNP as a proxy for rs1801282, we combined a random-effects meta-analysis result from Zeggini et al. (26) with a random-effects meta-analysis of nonoverlapping studies from our own searches. We first computed the summary log odds ratio and its variance for each data source and then computed the total sum of weights and the total sum of (weight x log odds ratios) across both sources, and used these to produce an overall summary estimate and variance. This is equivalent to a standard random-effects meta-analysis, with the exception that an estimate of between-study variance among Zeggini et al.'s (26) studies is used in the weights for those studies and an estimate of between-study variance among our studies is used in the weights for our studies.
###end p 28
###begin title 29
RESULTS
###end title 29
###begin title 30
Characteristics of the included studies
###end title 30
###begin p 31
###xml 636 643 636 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1172 1179 1172 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1355 1367 <span type="species:ncbi:9606">participants</span>
Our literature searches yielded 1,734 reports, from which 74 eligible studies were identified, in addition to 30 genome-wide association studies (W1-W85) ( and  and ). Sixty-six studies () contributed to the present review (W1-W7, W9-W14, W17, W19-W21, W23, W25, W27-W34, W36, W37, W40-W45, W47-W54, W56, W59, W61, W63, W65, W67, W68, W70, W72, W74, W79, W80, W83, W85). Nine studies from 7 papers (W35, W46, W55, W57, W77, W78, W81) (comprising approximately 7% of eligible cases and 10% of eligible controls) could not be included because of insufficient detail and lack of response from authors after our attempts at correspondence (Table 2). Researchers from the European Prospective Investigation Into Cancer and Nutrition (EPIC) provided unpublished data. Study-level characteristics for the EPIC study (27) and the EPIC nested case-control data have been previously published (supplementary materials of Zeggini et al. (26)); summary details are available in  () and  (). We also identified 30 genome-wide association studies of type 2 diabetes in 16 papers published since 2007 (W18, W22, W24, W26, W58, W60, W62, W64, W66, W69, W71, W73, W75, W76, W82, W84) (see Table 3 and  ()). Each of these studies included either the Pro12Ala variant (rs1801282) or a nearby tagging SNP. Zeggini et al. (26) presented results from a meta-analysis of 59,682 participants across several of these genome-wide association studies (W62, W64, W73, W84).
###end p 31
###begin p 32
###xml 105 111 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
Characteristics of Genetic Association Studies of the Peroxisome Proliferator-Activated Receptor-gamma2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes That Were Potentially Eligible for Inclusion in the Current Analysis but Did Not Have Full Genotype Data Available, 2000-2006
###end p 32
###begin p 33
Abbreviations: C-C, case-control; GP, general population; HWE, Hardy-Weinberg equilibrium; NS, not stated; RFLP, restriction fragment length polymorphism; SD, standard deviation; WHO, World Health Organization.
###end p 33
###begin p 34
Characteristics of the Genome-Wide Association Studies Conducted for Type 2 Diabetes, 2007-2009
###end p 34
###begin p 35
Abbreviations: BMI, body mass index; NS, not stated; SD, standard deviation.
###end p 35
###begin p 36
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Weight (kg)/height (m)2.
###end p 36
###begin p 37
Numbers in brackets, number of subjects.
###end p 37
###begin p 38
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
The identified studies were published between 1998 and 2008 and were undertaken in a wide range of geographic settings, with 66% (21,670 of 32,849) of cases having white European continental ancestry (Caucasian), 25% (8,187 of 32,849) being East Asian, and 9% (2,992 of 32,849) having other ethnic origins (including African-American, American Indian, or not stated). Nine studies were described as prospective in design, 3 were described as cross-sectional studies, 8 as genome-wide association studies, and 47 as case-control studies. Thirty-one studies involved general population-based controls, 4 involved hospital-based controls, and 1 involved health-care employees; in 13 studies, investigators did not describe the source of their controls (see ). In 32 studies, authors reported using World Health Organization criteria for diagnosis of type 2 diabetes (28). Restriction fragment length polymorphism analysis was the most common method of genotyping used. In 23 studies, authors did not report any information on the BMI of the case group (see ). In 11 studies, investigators reported information regarding age at disease onset. Of the 67 included studies, 60 provided data for the per-allele genetic model in our presented analyses (W1-W4, W6, W7, W9-W14, W17-W21, W25-W33, W36, W37, W40-W45, W47-W50, W52-W54, W56, W59, W61, W63-W65, W67, W71, W74, W84, W85).
###end p 38
###begin p 39
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Two studies were found to deviate from Hardy-Weinberg equilibrium according to the test P value (P < 0.05) (W2, W5). Approximately 70% of the studies had fixation coefficients with absolute values larger than 0.03 (median, -0.004; range, -0.072 to 0.185), with the studies evenly distributed around zero. Authors in 42 studies reported testing for Hardy-Weinberg equilibrium and found no deviation (see  and ).
###end p 39
###begin title 40
Associations
###end title 40
###begin p 41
###xml 545 546 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 587 589 587 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
In a random-effects meta-analysis with a per-allele genetic model, the combined type 2 diabetes odds ratio for the Pro12Ala polymorphism across the 66 studies was 0.86 (95% confidence interval (CI): 0.81, 0.90) ( ()). The fixed-effect meta-analysis was 0.85 (95% CI: 0.82, 0.88). The cumulative meta-analysis illustrates the exaggerated effect often observed in the earliest study and reveals that the accumulated evidence hovered around the conventional 5% significance level until 2004. In studies published between 2004 and 2008, the overall P value was reduced from 0.028 to 1.3 x 10-8.
###end p 41
###begin p 42
###xml 111 117 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG2</italic>
###xml 255 256 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Results from random-effects meta-analyses of studies of the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes according to various study-level characteristics. BMI, body mass index (weight (kg)/height (m)2); CI, confidence interval; GWA, genome-wide association.
###end p 42
###begin p 43
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 380 388 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 497 498 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 498 499 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 662 663 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 686 687 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 760 761 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 761 762 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 785 786 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 857 858 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 991 992 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 992 993 992 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 232 243 <span type="species:ncbi:9606">participant</span>
There was evidence of a moderate degree of inconsistency among these studies (I2 = 37%, 95% CI: 9, 54; P = 0.0028), and no evidence of funnel plot asymmetry was found either visually or using the Harbord test (23) (P = 0.87). Study participant ethnicity accounted for some of this heterogeneity (14% of the between-study variance). Results from subgroup analyses are presented in Figure 1. When we considered only the large (>500 cases) studies, the odds ratio was 0.84 (95% CI: 0.79, 0.90), with I2 = 43% (95% CI: 0, 66; P = 0.025). When studies were subgrouped by ethnicity, the odds ratio was nearer 1 for Caucasians (odds ratio = 0.86 (95% CI: 0.81, 0.90), I2 = 37% (95% CI: 0, 57; P = 0.019)) than for East Asians (odds ratio = 0.78 (95% CI: 0.65, 0.99), I2 = 45% (95% CI: 0, 69; P = 0.031)), although the difference was not statistically significant (P = 0.38). A dominant analysis of all studies composed of Asian populations produced an odds ratio of 0.80 (95% CI: 0.66, 0.97), with I2 = 40.5% (95% CI: 0, 64).
###end p 43
###begin p 44
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The combined odds ratio for studies with a mean case BMI less than 25 was 0.88 (95% CI: 0.68, 1.13), with I2 = 57% (95% CI: 0, 78; P = 0.016). Studies with a mean case BMI between 25 and 29.9 had an odds ratio of 0.84 (95% CI: 0.77, 0.91), with I2 = 0% (95% CI: 0, 47; P = 0.45). Studies with a mean case BMI greater than or equal to 30 had an odds ratio of 0.90 (95% CI: 0.82, 0.99), with I2 = 46% (95% CI: 0, 68; P = 0.024). A test for trend across these 3 groups was not statistically significant (P = 0.49).
###end p 44
###begin p 45
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 352 353 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 576 577 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
No statistically significant differences were observed according to study design. Forty case-control studies had an odds ratio of 0.85 (95% CI: 0.79, 0.92), with I2 = 44%; 9 prospective studies had an odds ratio of 0.88 (95% CI: 0.74, 1.04), with I2 = 35%; and the 8 genome-wide association studies had an odds ratio of 0.84 (95% CI: 0.79, 0.89), with I2 = 0%. Only 3 cross-sectional studies were available. Only in 10 studies did authors report blinding, and among those studies that did not report blinding status, the pooled odds ratio was 0.86 (95% CI: 0.77, 0.97), with I2 = 63.
###end p 45
###begin p 46
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 410 411 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 418 419 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 561 562 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 640 641 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
We also investigated potential variation arising from the use of different sources of controls. In 42 studies, investigators reported the use of a general population cohort as their control group; the combined odds ratio was 0.86 (95% CI: 0.81, 0.91), with I2 = 38%. In only 4 studies did authors report the use of hospital-based controls; in those studies, the odds ratio was 1.09 (95% CI: 0.86, 1.37), with I2 = 0% (P = 0.06 in comparison with general population controls), while in those studies for which authors did not state the source of their controls (n = 11), the pooled odds ratio was 0.77 (95% CI: 0.64, 0.93), with I2 = 21.1% (P = 0.26 in comparison with general population controls).
###end p 46
###begin p 47
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 279 287 279 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 261 273 <span type="species:ncbi:9606">participants</span>
We combined the random-effects meta-analysis of Zeggini et al. (26) with our own random-effects meta-analysis of nonoverlapping published literature-based studies to produce an overall pooled odds ratio of 0.88 (95% CI: 0.84, 0.92) involving a total of 116,040 participants (see Figure 1).
###end p 47
###begin title 48
DISCUSSION
###end title 48
###begin title 49
Main findings
###end title 49
###begin p 50
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 625 630 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
This HuGE association review involved an updated meta-analysis of the relation between the PPARG Pro12Ala polymorphism and type 2 diabetes among 32,849 cases and 47,456 controls in 60 studies (counting every study's cases and controls only once). The PPARG 12Ala polymorphism was associated with a reduction in type 2 diabetes risk (odds ratio = 0.86, 95% CI: 0.81, 0.90), and this confirms findings from previous meta-analyses (29-35). When only the largest studies (>500 cases) were considered, the association remained stable (odds ratio = 0.84, 95% CI: 0.79, 0.90). This work further confirms the association between the PPARG Pro12Ala polymorphism and type 2 diabetes.
###end p 50
###begin p 51
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 451 463 <span type="species:ncbi:9606">participants</span>
The results of the Zeggini et al. (26) meta-analysis of genome-wide association studies were compatible with our own literature-based meta-analysis. The Zeggini et al. analysis provided an estimate that minimized publication bias because of the availability of genotype data from a consortium-based approach. We pooled this estimate with our own estimate from nonoverlapping published literature association studies to produce an estimate for 116,040 participants. Proposed guidelines for assessing the strength of evidence from gene-disease association studies (36) would designate the findings for Pro12Ala and type 2 diabetes as "strong" evidence (see  ()).
###end p 51
###begin title 52
Limitations
###end title 52
###begin p 53
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
When interpreting these results, the potential limitations of such a report should be considered. First, the key threat to any literature-based review and meta-analysis is that of reporting bias (where only the most exciting findings are available in the published literature). Although our own assessments did not generally suggest the presence of material publication bias, it is not possible to rule it out entirely (37, 38). Given the consistency of findings between our main analysis and our analysis of only the large (>500 cases) studies, which should have been less prone to selective reporting, we may place reasonable confidence in our observations. Our findings were also consistent with the results from Zeggini et al.'s meta-analysis of genome-wide association studies (26).
###end p 53
###begin title 54
Consistency across studies
###end title 54
###begin p 55
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Overall, I2 was estimated to be 37%, with statistically significant evidence of heterogeneity. This represents a moderate level of inconsistency attributable to genuine variation in gene effect size. It has been hypothesized in the past that this may reflect variation between ethnic populations. We observed a slightly higher magnitude of association in East Asians compared with Caucasians, but the difference was not statistically significant. Polymorphism frequencies are known to vary by ethnicity, but the effect of this on risk remains insufficiently studied. In the studies we identified, the frequency of the 12Ala polymorphism in controls was observed to be greater in Caucasian populations than in East Asian populations.
###end p 55
###begin p 56
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
The observed difference in the magnitude of association between these populations may also be explained partly by differences in BMI. In a study of French Caucasians conducted by Ghoussaini et al. (W20), the presence of the Pro12 variant was observed to double the risk of type 2 diabetes in the obese subpopulation. However, the Ala12 variant has also been shown to be weakly associated with higher BMI, as confirmed in a meta-analysis conducted in 2003 by Masud et al. (39).
###end p 56
###begin p 57
A meta-analysis conducted by Ludovico et al. (W37) found that the alanine polymorphism conferred significantly greater protection against type 2 diabetes among Asians than among Caucasians. Using 10 studies of Asian populations, their results revealed an odds ratio of 0.65 (95% CI: 0.54, 0.79). When the analysis was adjusted for BMI in the controls, this statistical significance was lost. Furthermore, taking into account body fat content and distribution, Radha et al. (W57) found no protective effect of the Pro12Ala polymorphism in South Asians.
###end p 57
###begin p 58
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 423 431 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
We conducted a similar analysis of results from 20 relevant studies (using a dominant model) which showed an odds ratio of 0.80 (95% CI: 0.66, 0.97) and suggested no difference between Asians and Caucasians (P = 0.59). Studies in which cases had a lower mean BMI observed a slightly greater protective effect of the 12Ala polymorphism on type 2 diabetes risk, but this was not statistically significant (P = 0.57; see also Figure 1).
###end p 58
###begin p 59
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
In 2001, Luan et al. (40) hypothesized a gene-nutrient interaction based on the ratio of polyunsaturated fats to saturated fats which determined the association between the Pro12Ala polymorphism and BMI. This study may contribute towards an explanation of the role played by ethnicity and differences in dietary habits. However, more recently, Robitaille et al. (41) suggested an interaction in the opposite direction, highlighting the need to carefully assess possible interactions.
###end p 59
###begin p 60
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 201 204 <span type="species:ncbi:9606">men</span>
###xml 209 214 <span type="species:ncbi:9606">women</span>
###xml 355 358 <span type="species:ncbi:9606">men</span>
###xml 379 384 <span type="species:ncbi:9606">women</span>
Another potential source of variation has been identified by Hegele et al. (W25) and Radha et al. (W57): These authors noted differences in the association between Pro12Ala and type 2 diabetes between men and women. More recently, Ali et al. (W1), Morini et al. (42), and Mattevi et al. (43) observed a relation between the polymorphism and higher BMI in men which was absent in women. Since few investigators publish their data stratified by sex, we were unable to investigate these issues in detail. Although these investigations have been inconsistent in the past, differences in the phenotypic consequences of the Pro12Ala polymorphism among males and females warrant further investigation. Further studies of gene-gene and gene-environment interaction are necessary to better understand these relations.
###end p 60
###begin title 61
Biology
###end title 61
###begin p 62
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 476 478 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 579 585 <span type="species:ncbi:9606">people</span>
The substitution from proline to alanine at codon 12 has been found to modulate transcriptional activity (44, 45). This substitution is close to the NH2-terminus of the protein in the ligand-independent activation domain, the activity of which is potentiated through phosphorylation by insulin. The structure and consequently the function of the protein may be affected by this amino acid change, since alanine favors the formation of alpha-helices while proline prevents it (46). The alanine isoform leads to the less efficient stimulation of PPARG target genes and predisposes people to lower levels of adipose tissue mass accumulation, which in turn may improve insulin sensitivity-thus supporting the protective effect observed for 12Ala carriers, since decreased insulin sensitivity plays a central role in the pathogenesis of type 2 diabetes.
###end p 62
###begin title 63
Potential public health impact and other implications of results
###end title 63
###begin p 64
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">50</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 758 765 <span type="species:ncbi:9606">persons</span>
There is evidence that PPARG supports the "thrifty gene hypothesis" in that the wild-type genotype optimizes the building of fat deposits as energy reserves and thus favored human survival in times when food was either limited, sporadically available, or poor in quality (47-50). Because today's lifestyle is much more relaxed and sedentary and is characterized by a diet that is rich in carbohydrates and fats and poor in fiber, these once favorable genetic factors have now become detrimental, leading to an increase in the risk of developing chronic diseases such as type 2 diabetes. PPARG is a known target for thiazolidinediones, antidiabetic drugs which have been shown to improve insulin sensitivity and to reduce plasma glucose and blood pressure in persons with type 2 diabetes (51). Thiazolidinediones are highly specific ligands for PPARG and lead to the activation of the nuclear receptor on binding (52).
###end p 64
###begin p 65
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 53 59 <span type="species:ncbi:9606">humans</span>
Since the Pro12 allele is present in at least 80% of humans, the population attributable risk of type 2 diabetes associated with this polymorphism is as high as 25% (30). This gene is a confirmed type 2 diabetes susceptibility locus and is now one of almost 20 type 2 diabetes susceptibility loci identified over the last few years. With other type 2 diabetes susceptibility loci, research on how best to use this information in a translational context is needed. Given the possible heterogeneity in the magnitude of the association among populations and with environmental factors, a more systematic assessment locus should also be used as a genetic factor with which to investigate both gene-gene and gene-environment interactions with type 2 diabetes.
###end p 65
###begin title 66
Supplementary Material
###end title 66
###begin title 67
[Appendix, Figure 1 and Tables 1-4]
###end title 67
###begin title 68
Abbreviations
###end title 68
###begin p 69
body mass index
###end p 69
###begin p 70
confidence interval
###end p 70
###begin p 71
European Prospective Investigation Into Cancer and Nutrition
###end p 71
###begin p 72
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Genome Epidemiology
###end p 72
###begin p 73
peroxisome proliferator-activated receptor-gamma
###end p 73
###begin p 74
single nucleotide polymorphism
###end p 74
###begin p 75
###xml 147 151 <span type="species:ncbi:71606">Hebe</span>
Author affiliations: Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom (Hebe N. Gouda, Jan Yates); Strangeways Research Laboratory, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom (Gurdeep S. Sagoo, Manjinder S. Sandhu, Julian P. T. Higgins); MRC Biostatistics Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom (Gurdeep S. Sagoo, Julian P. T. Higgins); and MRC Epidemiology Unit, Institute of Public Health, University of Cambridge, Cambridge, United Kingdom (Anne-Helen Harding).
###end p 75
###begin p 76
The work of Drs. Gurdeep S. Sagoo and Julian P. T. Higgins was funded by a grant from the PHG Foundation. Dr. Julian P. T. Higgins was supported by Medical Research Council grant U.1052.00.011.
###end p 76
###begin p 77
The authors thank Drs. Phillippe Amouyel, Leslie J. Baier, Jens P. Berg, Michael Boehnke, Raffaella Buzetti, Young Min Cho, Coleen Damcott, Ian Deary, Paul Franks, Philippe Froguel, David Flavell, Jose Florez, Maya Ghoussaini, Leif Groop, Robert Hegele, Christian Herder (and all collaborators in the KORA genome-wide association study), Joel Hirschorn, Wendy Johnson, Takashi Kadowaki, Tuomas Kilpelainen, Ornella Ludovico, Valeriya Lyssenko, Maciek Malecki, James Meigs, Aline Meirhaeghe-Hurez, Reza Meshkani, Luis Gallert Millan, Yunhua Muller, Jill Norris, Kyong Soo Park, Oluf Borbye Pederson, Fabio Pellegrini, Raul Pisabarro, Alan Shuldiner, Inmaculada Simon, Soren Snitker, Daniela Sramkova, Heather Stringham, Vlad Tavares, Andrew Thomas, Per Thorsby, Vincenzo Trischitta, Olga Vaccaro, and Eleftheria Zeggini for correspondence and for contributing data.
###end p 77
###begin p 78
Conflict of interest: none declared.
###end p 78
###begin article-title 79
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
###end article-title 79
###begin article-title 80
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor
###end article-title 80
###begin article-title 81
Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases
###end article-title 81
###begin article-title 82
###xml 61 66 <span type="species:ncbi:9606">human</span>
Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists
###end article-title 82
###begin article-title 83
###xml 59 64 <span type="species:ncbi:9606">human</span>
The organization, promoter analysis, and expression of the human PPARgamma gene
###end article-title 83
###begin article-title 84
Genetics of leptin and obesity: a HuGE review
###end article-title 84
###begin article-title 85
###xml 26 31 <span type="species:ncbi:9606">human</span>
Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPARgamma) gene in diabetic Caucasians: identification of a Pro12Ala PPARgamma 2 missense mutation
###end article-title 85
###begin article-title 86
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
###end article-title 86
###begin article-title 87
Global and societal implications of the diabetes epidemic
###end article-title 87
###begin article-title 88
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
###end article-title 88
###begin article-title 89
Type-2 diabetes: a cocktail of genetic discovery
###end article-title 89
###begin article-title 90
The search for type 2 diabetes genes
###end article-title 90
###begin article-title 91
Progress in defining the molecular basis of type 2 diabetes mellitus through susceptibility-gene identification
###end article-title 91
###begin article-title 92
A new era for type 2 diabetes genetics
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human genetic variation and its contribution to complex traits
###end article-title 93
###begin article-title 94
Genome-wide association studies provide new insights into type 2 diabetes aetiology
###end article-title 94
###begin article-title 95
Casting a wider net for diabetes susceptibility genes
###end article-title 95
###begin article-title 96
Systematic reviews of genetic association studies [electronic article]
###end article-title 96
###begin article-title 97
An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization
###end article-title 97
###begin article-title 98
A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints
###end article-title 98
###begin article-title 99
Meta-analysis in clinical trials
###end article-title 99
###begin article-title 100
Measuring inconsistency in meta-analyses
###end article-title 100
###begin article-title 101
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes
###end article-title 101
###begin article-title 102
EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer
###end article-title 102
###begin article-title 103
Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk
###end article-title 103
###begin article-title 104
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
###end article-title 104
###begin article-title 105
Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians
###end article-title 105
###begin article-title 106
Is the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene associated with type 2 diabetes? A meta-analysis [abstract]
###end article-title 106
###begin article-title 107
The role of PPARgamma in the onset of type 2 diabetes [in Japanese]
###end article-title 107
###begin article-title 108
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease
###end article-title 108
###begin article-title 109
Candidate genes for type 2 diabetes
###end article-title 109
###begin article-title 110
Assessment of cumulative evidence on genetic associations: interim guidelines
###end article-title 110
###begin article-title 111
Problems of reporting genetic associations with complex outcomes
###end article-title 111
###begin article-title 112
Genetic associations in large versus small studies: an empirical assessment
###end article-title 112
###begin article-title 113
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis
###end article-title 113
###begin article-title 114
Evidence for gene-nutrient interaction at the PPARgamma locus
###end article-title 114
###begin article-title 115
The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study
###end article-title 115
###begin article-title 116
Interaction between PPARgamma2 variants and gender on the modulation of body weight
###end article-title 116
###begin article-title 117
Effects of a PPARG gene variant on obesity characteristics in Brazil
###end article-title 117
###begin article-title 118
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
###end article-title 118
###begin article-title 119
Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis
###end article-title 119
###begin article-title 120
Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin
###end article-title 120
###begin article-title 121
Peroxisome proliferator-activated receptor gamma: the more the merrier?
###end article-title 121
###begin article-title 122
The thrifty genotype in type 2 diabetes: an unfinished symphony moving to its finale?
###end article-title 122
###begin article-title 123
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?
###end article-title 123
###begin article-title 124
Is the Ala12 variant of the PPARG gene an "unthrifty allele"?
###end article-title 124
###begin article-title 125
Thiazolidinediones: a new class of antidiabetic drugs
###end article-title 125
###begin article-title 126
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma)
###end article-title 126

